ÂÜÀòÂÒÂ×

Nick is an internationally recognized drug discovery and development specialist who has spent nearly 40 years working in the field. Previous roles include research appointments at Eli Lilly, Lundbeck Research USA, and Albany Molecular Research Inc. (AMRI) and scientific advisory roles at Brains On-Line (now part of Charles River Laboratories). Nick earned a doctorate in Neuropharmacology from the University of Birmingham, England. Career highlights include leading the preclinical team involved in the development of Lilly’s antipsychotic drug Zyprexa (olanzapine) and Lundbeck’s antidepressant Trintellix/Brintellix (vortioxetine). In 1999, he received the prestigious ‘Society for Medicines Research Award for Drug Discovery’ for his contributions to the discovery and development of Zyprexa.